SCHEDULE OF STOCK OPTIONS

	Number of Shares			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value

Outstanding – January 1, 2020		797,373		$	1.99	$	0.72		5.0	$	—
Granted		378,800		$	0.94		5.22
Expired forfeited, or cancelled		(246,408	)	$	1.94		0.88
Outstanding – December 31, 2020		929,765		$	1.53	$	2.50		6.1	$	2,537,245
Granted		124,100		$	2.98	$	2.32
Options assumed pursuant to acquisition of MagicMed		973,840		$	1.34	$	1.84
Exercised		(143,796	)	$	0.23	$	5.69
Expired forfeited, or cancelled		(692,475	)	$	1.69	$	1.62
Outstanding – December 31, 2021		1,191,434		$	1.58	$	2.07		5.3	$	34,333

Exercisable at December 31, 2021		958,915		$	1.50	$	2.01		4.5	$	13,733

The following table summarizes information about shares issuable under warrants outstanding at December 31, 2021:

SCHEDULE OF WARRANTS

	Warrant shares outstanding			Weighted average exercise price		Weighted average remaining life		Intrinsic value
Outstanding at January 1, 2021		3,730,805		$	2.05		5.2	$	8,923,797
Granted		4,146,146		$	4.20
Assumed pursuant to acquisition of MagicMed		5,913,672		$	1.31
Exercised		(3,253,714	)	$	1.01
Exchanged for common stock		(768,143	)	$	4.65
Outstanding at December 31, 2021		9,768,766		$	2.62		3.4	$	801,024

The warrants assumed pursuant to the acquisition of MagicMed contain certain down round features, which were not triggered by the February 2022 public offering, that would require adjustment to the exercise price upon certain events when the offering price is less than the stated exercise price.

All outstanding warrants are exercisable.

Warrants exchanged for Common Stock consist of an aggregate of 221,653 shares of Common Stock being issued in exchange for an aggregate of 109,372 warrants issued by Ameri and containing put rights that were exercised by the Holder and an aggregate of 973,190 shares of Common Stock being issued in exchange for an aggregate of 658,771 warrants containing certain terms wherein management determined it to be beneficial to the Company to exchange Common Shares for these warrants.

The aggregate of 221,653 Common Shares issued in exchange for the aggregate of 109,372 warrants issued by Ameri and containing put rights were issued in lieu of cash payments, in accordance with the terms of the put rights contained in the warrants.

The aggregate of 973,190 shares of common stock issued in exchange for certain outstanding warrants to purchase an aggregate of 658,771 shares of the Company’s common stock at an exercise price of $4.66 were issued pursuant to exchange agreements with the holders of such warrants. The Company believes that these exchanges are beneficial to the Company because the reacquired warrants contained provisions that required the Company to repurchase the warrants for cash at the holder’s option and/or “full ratchet” anti-dilution adjustments that may result in a reduction in the exercise price of such warrants and an increase in the number of shares issuable upon exercise thereof under certain circumstances. The Company has cancelled all of the warrants reacquired in such exchanges and they will not be reissued. In connection with this exchange, the Company recognized $826,577 in inducement expense related to the increase in fair value of the new awards over the old awards, which is included in other expenses on the Company’s consolidated statement of operations and comprehensive loss.

The following table summarizes information about shares issuable under warrants outstanding at December 31, 2020:

Number of Shares Weighted Average Exercise Price (USD) Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (USD)

Outstanding – January 1, 2020 303,891 $ 1.99 1.06 —

Granted 3,701,730 $ 0.94

Expired forfeited, or cancelled (274,816 ) $ 1.94

Outstanding – December 31, 2020 3,730,805 $ 2.05 5.2 $ 8,923,797

Exercisable at December 31, 2020 3,730,805 $ 2.05 5.2 $ 8,923,797

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY

The Company’s activity in restricted stock units was as follows for the year ended December 31, 2021 (there were no restricted stock units issued for the year ended December 31, 2020):

	Number of shares			Weighted average fair value
Non–vested at January 1, 2021		—		$	—
Granted		6,258,377		$	3.44
Forfeited		(371,944	)	$	3.04
Vested		(2,785,820	)	$	4.52
Non–vested at December 31, 2021		3,100,613		$	2.52